{"analyses":[{"ciLowerLimit":"0.83","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.58","estimateComment":"Common treatment odds ratio stratified by geographic region (North America, western Europe and Australia vs rest of world) and ECOG performance status (0 or 1 vs 2).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Odds Ratio (OR)","paramValue":"1.15"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.34","upperLimit":"23.62","value":"19.79"},{"groupId":"OG001","lowerLimit":"18.41","upperLimit":"25.97","value":"22.02"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"485"},{"groupId":"OG001","value":"486"}],"units":"Participants"}],"description":"Objective response is either a complete response (CR) or partial response (PR) per RECIST version 1.1. All participants that did not meet the criteria for an objective response by the analysis cut-off date were considered non-responders. CR: Disappearance of all target lesions, any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm, and disappearance of all non-target lesions, and no new lesions. PR: Disappearance of all target lesions, persistence of one or more non-target lesions not qualifying for either CR or progressive disease, or, at least a 30% decrease in the sum of diameters of target lesions with no unequivocal progression of existing non-target lesions and no new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Cetuximab 400 mg/m\\^2 as an initial dose, followed by 250 mg/m\\^2 intravenously (IV) every 7 days.","id":"OG000","title":"Cetuximab"},{"description":"Panitumumab 6 mg/kg IV every 14 days.","id":"OG001","title":"Panitumumab"}],"paramType":"NUMBER","populationDescription":"Tumor Response Analysis Set: Participants in the primary analysis set with at least 1 Baseline unidimensionally measurable lesion per RECIST version 1.1.","reportingStatus":"POSTED","timeFrame":"From randomization until the data cut-off date of 5 February 2013. Maximum time on study was 155 weeks.","title":"Objective Response","type":"SECONDARY","unitOfMeasure":"percentage of participants"}